MY127812A - New use for budesonide and formoterol - Google Patents

New use for budesonide and formoterol

Info

Publication number
MY127812A
MY127812A MYPI98004288A MYPI9804288A MY127812A MY 127812 A MY127812 A MY 127812A MY PI98004288 A MYPI98004288 A MY PI98004288A MY PI9804288 A MYPI9804288 A MY PI9804288A MY 127812 A MY127812 A MY 127812A
Authority
MY
Malaysia
Prior art keywords
formoterol
budesonide
new use
treatment
provides
Prior art date
Application number
MYPI98004288A
Other languages
English (en)
Inventor
Carl-Axel Bauer
Jan Trofast
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY127812(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of MY127812A publication Critical patent/MY127812A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI98004288A 1997-09-19 1998-09-18 New use for budesonide and formoterol MY127812A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703407A SE9703407D0 (sv) 1997-09-19 1997-09-19 New use

Publications (1)

Publication Number Publication Date
MY127812A true MY127812A (en) 2006-12-29

Family

ID=20408325

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI98004288A MY127812A (en) 1997-09-19 1998-09-18 New use for budesonide and formoterol

Country Status (38)

Country Link
US (2) US7897646B2 (member.php)
EP (2) EP1210943B1 (member.php)
JP (1) JP2001517630A (member.php)
KR (1) KR20010024140A (member.php)
CN (1) CN1149998C (member.php)
AR (1) AR013506A1 (member.php)
AT (2) ATE329599T1 (member.php)
AU (1) AU757235B2 (member.php)
BR (1) BR9812325A (member.php)
CA (1) CA2302700C (member.php)
CY (1) CY1106156T1 (member.php)
CZ (1) CZ295250B6 (member.php)
DE (2) DE69807239T2 (member.php)
DK (2) DK1014993T3 (member.php)
EE (1) EE04297B1 (member.php)
ES (2) ES2182357T3 (member.php)
HK (1) HK1045812B (member.php)
HU (1) HUP0003848A2 (member.php)
ID (1) ID24838A (member.php)
IL (1) IL134773A (member.php)
IN (1) IN190791B (member.php)
IS (1) IS2715B (member.php)
MX (1) MXPA00002615A (member.php)
MY (1) MY127812A (member.php)
NO (1) NO327176B1 (member.php)
NZ (1) NZ503173A (member.php)
PL (1) PL190782B1 (member.php)
PT (2) PT1014993E (member.php)
RU (1) RU2199322C2 (member.php)
SA (1) SA98190773B1 (member.php)
SE (1) SE9703407D0 (member.php)
SI (2) SI1014993T1 (member.php)
SK (1) SK285330B6 (member.php)
TR (1) TR200000726T2 (member.php)
TW (1) TW546140B (member.php)
UA (1) UA72446C2 (member.php)
WO (1) WO1999015182A1 (member.php)
ZA (1) ZA988516B (member.php)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
NZ511527A (en) * 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
BR0207062A (pt) * 2001-02-06 2004-10-05 Innovata Biomed Ltd Composição farmacêutica bimodal, inalador para pó seco, método de aplicação de uma quantidade terapeuticamente eficaz de um ingrediente ativo substancialmente fino aos pulmões de um paciente, método de tratamento de um distúrbio respiratório, método de tratamento de doença pulmonar obstrutiva crÈnica (copd), uso de um agente antiinflamatório, uso de um broncodilatador, uso de uma mistura de um agente antiinflamatório e de um broncodilatador, e, processo para a fabricação de uma composição farmacêutica bimodal
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
AU2003279070A1 (en) * 2002-09-30 2004-04-23 Acusphere Inc Sustained release porous microparticles for inhalation
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
BRPI0613034A8 (pt) 2005-07-14 2018-01-02 Lipothera Inc formulação injetável para acúmulo de tecido adiposo, formulação injetável e método para o tratamento de acúmulo de gordura, e, método para reduzir o tecido adiposo.
CA2631492A1 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
ES2398480T3 (es) * 2006-10-17 2013-03-19 Lithera, Inc. Procedimientos, composiciones, y formulaciones para el tratamiento de la enfermedad ocular tiroidea
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
SMT202000077T1 (it) 2009-05-29 2020-03-13 Pearl Therapeutics Inc Composizioni per il rilascio polmonare di antagonisti muscarinici a lunga durata e agonisti dei recettori beta-2 adrenergici a lunga durata e metodi e sistemi associati
CA2764867C (en) * 2009-06-09 2016-05-17 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CN102000090A (zh) * 2009-08-31 2011-04-06 北京利乐生制药科技有限公司 一种以布地奈德与阿福特罗为活性成分的复方制剂
SG2014014351A (en) * 2010-01-15 2014-07-30 Lithera Inc Lyophilized cake formulations
WO2012074856A2 (en) 2010-11-24 2012-06-07 Lithera, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
CA2830069C (en) 2011-03-20 2019-11-12 The University Of British Columbia Therapeutic agent for emphysema and copd
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
MX361286B (es) 2013-03-15 2018-12-03 Pearl Therapeutics Inc Métodos y sistemas para el acondicionamiento de materiales cristalinos de partículas.
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
WO2015065220A1 (ru) * 2013-10-28 2015-05-07 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201321712D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
ES2866175T3 (es) 2015-12-04 2021-10-19 Mexichem Fluor Sa De Cv Composición farmacéutica
WO2019241580A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition
WO2021048171A1 (en) * 2019-09-10 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
US12329759B2 (en) 2019-10-17 2025-06-17 Trustees Of Boston University Methods and compositions relating to lung function

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235222A (en) 1989-09-08 1992-11-25 Glaxo Group Ltd Inhalatory composition comprising salmeterol and beclomethasone dipropionate
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
SK285910B6 (sk) * 1991-12-18 2007-10-04 Aktiebolaget Astra Medicinálny produkt obsahujúci kombináciu formoterolu a budesonidu
EP1086697A2 (en) 1991-12-18 2001-03-28 AstraZeneca AB New combination of formoterol and budesonide
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
GB9519692D0 (en) * 1995-09-27 1995-11-29 Quillin Helen Atomising nozzle
CN1207730A (zh) * 1995-11-24 1999-02-10 史密丝克莱恩比彻姆股份公司 喹啉衍生物
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
EP1009408A1 (en) 1997-06-27 2000-06-21 Astra Aktiebolag New combination of antiasthma medicaments
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination

Also Published As

Publication number Publication date
CZ2000950A3 (cs) 2000-06-14
NO20001401D0 (no) 2000-03-17
CA2302700A1 (en) 1999-04-01
ATE222106T1 (de) 2002-08-15
NZ503173A (en) 2001-08-31
CN1271287A (zh) 2000-10-25
US8461211B2 (en) 2013-06-11
US7897646B2 (en) 2011-03-01
MXPA00002615A (es) 2002-04-24
ES2266322T3 (es) 2007-03-01
JP2001517630A (ja) 2001-10-09
EP1210943A1 (en) 2002-06-05
CY1106156T1 (el) 2011-06-08
DE69807239D1 (de) 2002-09-19
BR9812325A (pt) 2000-09-05
PL190782B1 (pl) 2006-01-31
EE04297B1 (et) 2004-06-15
EP1014993A1 (en) 2000-07-05
US20110097282A1 (en) 2011-04-28
TR200000726T2 (tr) 2000-09-21
DE69807239T2 (de) 2003-04-10
AU9192898A (en) 1999-04-12
EP1014993B1 (en) 2002-08-14
HK1045812B (en) 2006-12-22
CA2302700C (en) 2010-11-23
KR20010024140A (ko) 2001-03-26
RU2199322C2 (ru) 2003-02-27
DE69834955T2 (de) 2007-01-25
SI1210943T1 (sl) 2006-10-31
WO1999015182A1 (en) 1999-04-01
AU757235B2 (en) 2003-02-06
HUP0003848A2 (hu) 2001-08-28
DE69834955D1 (de) 2006-07-27
US20060189587A9 (en) 2006-08-24
SA98190773B1 (ar) 2006-10-02
DK1014993T3 (da) 2002-11-11
IN190791B (member.php) 2003-08-23
SK285330B6 (sk) 2006-11-03
IL134773A0 (en) 2001-04-30
IS2715B (is) 2011-02-15
IS5407A (is) 2000-03-15
TW546140B (en) 2003-08-11
ES2182357T3 (es) 2003-03-01
EE200000145A (et) 2001-02-15
SI1014993T1 (en) 2003-02-28
IL134773A (en) 2005-03-20
UA72446C2 (uk) 2005-03-15
HK1045812A1 (en) 2002-12-13
ATE329599T1 (de) 2006-07-15
SK3892000A3 (en) 2000-12-11
ZA988516B (en) 1999-03-19
ID24838A (id) 2000-08-24
CN1149998C (zh) 2004-05-19
SE9703407D0 (sv) 1997-09-19
PL339295A1 (en) 2000-12-04
EP1210943B1 (en) 2006-06-14
DK1210943T3 (da) 2006-09-18
NO20001401L (no) 2000-03-17
AR013506A1 (es) 2000-12-27
US20020042404A1 (en) 2002-04-11
PT1210943E (pt) 2006-09-29
PT1014993E (pt) 2002-12-31
NO327176B1 (no) 2009-05-04
CZ295250B6 (cs) 2005-06-15

Similar Documents

Publication Publication Date Title
MY127812A (en) New use for budesonide and formoterol
IS5752A (is) Notkun á blöndu sem inniheldur formóteról og búdesóníð til að fyrirbyggja eða meðhöndla bráða-asma
NO20001754L (no) Prostaglandinagonister og anvendelse derav for behandling av benforstyrrelser
HUP0104676A3 (en) Compositions for the treatment of anorectal disorders and their use
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
HUP0400529A3 (en) Use of chlorpromazine and pentamidine for preparation of pharmaceutical compositions for the treatment of neoplastic disorders
IL141403A0 (en) Deleted adenoviruses and methods of making and administering the same
KR970704430A (ko) 전립선 질환, 자궁내막증 및 비만증의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of prostatic diseases endometriosis and obesity)
PT1246835E (pt) Sapogeninas substituídas e sua utilização
DE60133389D1 (de) Gabapentinanaloga für schlafstörungen
IL125446A0 (en) Pharmaceutical composition for the treatment of asthma allergy and inflammation
AU6083899A (en) Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
NO20001412D0 (no) Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
AP2003002753A0 (en) Use of salmeterol and fluticasone propionate combination
HUP0202048A3 (en) Use of alpha1betha1 integrin receptor inhibitors and tgf-betha1 inhibitors in the treatment of kidney disease
ZA97741B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders.
PL358375A1 (en) Medicaments for treating respiratory disorders comprising formoterol and fluticasone
GB9923078D0 (en) Sapogenin derivatives and their use
GB2370507B (en) Apparatus for the diagnosis and therapy of neuro-muscular and other tissue disorders
IT232384Y1 (it) Apparecchiatura per ipotermia e/o ipertermia terapeutica.
MD980129A (en) Antiherpetic remedy
AU6690898A (en) Composition for the treatment of exercise induced pulmonary hemorrhage and inhaler for administering said composition
ID28817A (id) Penggunaan turunan-turunan tetrahidropiridin (atau4-hidropiperidin)-butilazol dalam pembuatan obat untuk perawatan nyeri
AU2728301A (en) Combination therapy for the treatment of inflammatory and respiratory diseases
HUP0202416A3 (en) Novel pharmaceutical combination and it's use for the treatment of certain cardiovascular disorders